Expert Insights

Kristin Higgins, MD, Winship Cancer Institute, GA

Videos

SRS and Other Local Ablative Strategies in Patients With NSCLC and Oligometastases

10/15/2022

Dr Kristin Higgins provides an overview of her presentation at Great Debates and Updates in Lung Cancer covering ablative radiation & other local modalities in systemically treated patients with NSCLC and oligometastases.

Dr Kristin Higgins provides an...

10/15/2022

Oncology

Nasser Altorki, MD, Weill Cornell Medical College

Videos

Adjuvant Checkpoint Inhibitors in Resectable NSCLC

10/15/2022

Dr Nasser Altorki reviews his presentation on adjuvant checkpoint inhibitors for patients with resectable non-small cell lung cancer, from the 2022 Great Debates and Updates in Lung Cancer meeting in New York.

Dr Nasser Altorki reviews his...

10/15/2022

Oncology

Srdan Verstovsek, MD, University of Texas MD Anderson Cancer Center

Videos

FDA Approves Pemigatinib for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

10/14/2022

Srdan Verstovsek, MD, discusses the study that led to the recent FDA approval of pemigatinib for patients with relapsed or refractory myeloid/lymphoid neoplasms and an FGFR1 rearrangement.

Srdan Verstovsek, MD, discusses...

10/14/2022

Oncology

Ghasson Abou-Alfa, MD, Memorial Sloan Kettering Cancer Center

Sponsored

Videos

Meet the Experts: Challenging Cases in Advanced HCC

10/13/2022

In this session from the 2022 ESMO World Congress on Gastrointestinal Cancer, a panel of experts presents several challenging patient cases of HCC and discuss the treatment course taken for each case.

In this session from the 2022...

10/13/2022

Oncology

Sponsored

Videos

Meet the Experts: Customized Dosing for Kinase Inhibitors

10/13/2022

In this session from the 2022 ESMO World Congress on Gastrointestinal Cancer, Tanios Bekaii-Saab, MD, and Gerald Prager, MD, present on customized dosing for kinase inhibitors in patients with gastrointestinal cancers.

In this session from the 2022...

10/13/2022

Oncology

Videos

Pafolacianine to Detect Folate Receptor-Positive Ovarian Cancer

10/12/2022

Janos Tanyi, MD, shares results and insights from the phase 3 to confirm the safety and efficacy of pafolacianine for the detection of folate receptor-positive ovarian cancer.

Janos Tanyi, MD, shares results...

10/12/2022

Oncology

Christian Rothermundt, MD, Kantonsspital St Gallen

Videos

Enzalutamide Plus Metformin Conveyed No Benefit for Disease Control Rate of Patients With Metastatic Castration-Resistant Prostate Cancer

10/12/2022

Dr Christian Rothermundt reviews the results of a phase 2 trial presented at the 2022 ESMO Congress, which demonstrated that adding metformin to enzalutamide conveyed no benefit for disease control rate of patients with metastatic...

Dr Christian Rothermundt reviews...

10/12/2022

Oncology

Videos

BRCA Testing in the Era of PARP Inhibitors for Patients With Breast Cancer

10/12/2022

Mark Robson, MD, discusses BRCA testing and PARP inhibitors, a topic he presented at the 2022 GDU Women’s Oncology virtual meeting.

Mark Robson, MD, discusses BRCA...

10/12/2022

Oncology

Panel of Experts Discuss HER2 Targeting in Metastatic Colorectal Cancer

Sponsored

Videos

Optimizing Treatment Approaches and Evolution of HER2 Targeting in Metastatic Colorectal Cancer

10/12/2022

A panel of experts provide an overview of the biology of HER2 as an actionable target in patients with metastatic colorectal cancer and discuss data from early and current clinical trials exploring patients with HER2-positive disease.

A panel of experts provide an...

10/12/2022

Oncology

Sponsored

Videos

Tucatinib Plus Trastuzumab in HER2-Positive Metastatic Colorectal Cancer: Primary Analysis of the Mountaineer Trial

10/12/2022

Thierry Andre, MD, and John Strickler, MD, discuss the primary analyses from the pivotal phase 2 MOUNTAINEER trial of tucatinib in combination with trastuzumab in patients with HER2-positive metastatic colorectal cancer after 2 or more lines...

Thierry Andre, MD, and John...

10/12/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology